Document:

Exhibit 10.1

 

EMPLOYEE LEASING AND OVERHEAD ALLOCATION AGREEMENT

 

This EMPLOYEE LEASING AND OVERHEAD ALLOCATION AGREEMENT (the “Agreement”), dated July 1, 2016, is made and entered into by and between Napo Pharmaceuticals, Inc., a Delaware corporation (“Napo”), and Jaguar Animal Health, Inc., a Delaware corporation (“JAGX”), with reference to the following facts:

 

1.                                      Napo has Licensed (the “License”) to JAGX certain intellectual property and other rights of Napo related to the development and commercialization of crofelemer for animals (the “JAG Business”) in exchange certain other consideration as detailed in the License.

 

2.                                      JAGX currently employs those individuals identified on Exhibit A, each of whom has been providing services in connection with the Napo Business (the “Leased Employees”).  Napo desires to receive the benefit of the Leased Employees’ services pursuant to the terms and conditions of this Agreement.

 

3.                                      Napo and JAG desire to enter into this Agreement in order to set forth the terms under which JAGX will lease the Employees to Napo and be reimbursed for certain overhead costs identified on Exhibit A.

 

NOW, THEREFORE, in consideration of the mutual promises contained herein, the parties agree as follows:

 

1.                                      Term.  The assistance period (“Assistance Period”) shall commence on the date hereof and shall terminate on December 31, 2016, unless renewed by the mutual agreement of Napo and JAGX.  The term (“Term”) of this Agreement shall be for the Assistance Period unless it is extended by mutual written agreement of the parties or earlier terminated pursuant to Paragraph 5 hereof.

 

2.                                      Description of Services.  During the Term:

 

(a)                                 JAGX shall provide Napo with the Leased Employees to perform the same or substantially similar work for Napo with respect to the Napo Business as the Leased Employees are performing for JAGX with respect to the JAGX Business.;

 

(b)                                 Napo shall have the sole right to control and direct the Leased Employees as to the performance of their duties and the means by which such duties are performed; and

 

(c)                                  Other than to lease the Leased Employees to JAGX, JAGX shall not make any material changes in the terms and conditions of employment of the Leased Employees, including without limitation, in their salaries, wages, bonuses or employee benefits, except (i) in the ordinary course of business or (ii) as required by law or regulation.

 

3.                                      Fees and Expenses.  JAGX is providing Leased Employees (EXHIBIT A) to Napo at the rate of the dollar value of each of the following items: (i) such Leased Employee’s gross wages and/or salary owed by JAGX during each calendar month during the Term (before

 

 

any tax withholdings or other deductions); Federal and State taxes paid on behalf of such Leased Employee by JAGX during each calendar month during the Term; and health benefits paid on behalf of such Leased Employee by JAGX during each calendar month during the Term; multiplied by the percentage of such Leased Employee’s total hours worked during such calendar month that consisted of services performed for or on behalf of Napo which the parties agree shall be the “approximate percentage of time to be spent rendering services to or for the benefit of Napo” as will be submitted on a monthly time sheet by such each individual Leased Employee by JAGX to JAGX Payroll Department at the end of each calendar month during the Term, and (ii) $100 per month per employee working for the benefit of Napo for overhead and office expenses, and (iii) allocation of monthly rent expense based on FTE allocation for services performed between JAGX and Napo.  The Fees and Expenses will no longer be valid if the two companies merge during this agreement.  Napo’s fee and expense total payment to JAGX will be due and payable at the earlier of the end of the contract term, or before a Jaguar and Napo merger agreement is executed.

 

4.                                      Status of Employees and Responsibility for Taxes.  JAGX is the employer of the Leased Employees and will be responsible for payment of federal, state, and local income, social security, unemployment, and other payroll taxes, employment taxes and other taxes for which JAGX is responsible with respect to the Leased Employees, and shall withhold, file, and pay such taxes for each Leased Employee’s wages and other taxable compensation to the extent required by law.  JAGX shall indemnify and hold Napo harmless for any and all tax liabilities that Napo may incur arising out of, relating to, or resulting from this Agreement.

 

5.                                      Termination.  Notwithstanding any provision herein to the contrary, this Agreement may be terminated: (a) by either party upon not less than thirty (30) days’ prior written notice to the other; or (b) by mutual agreement of JAGX and Napo.  Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination.

 

6.                                      No Agent Authority.  Nothing in this Agreement shall be construed to treat either party as the other party’s partner, co-employer, joint employer, employee or agent, or to give either party the actual or apparent authority to bind the other party in any respect.

 

7.                                      Duties of Napo.  With respect to the Leased Employees, during the Term Napo shall:

 

(a)                                 maintain personnel policies and practices that ensure Napo’s compliance with all applicable federal, state, and local employment laws, including but not limited to Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Family and Medical Leave Act, the Fair Labor Standards Act, the Occupational Safety and Health Act, the California Labor Code, and California Government Code Section 12940 et seq. (collectively, the “Employment Laws”);

 

(b)                                 direct the work of the Leased Employees in accordance with the terms and conditions of this Agreement, the personnel policies and procedures of JAGX (including, but not limited to, its policies against discrimination and harassment), and in compliance with all of the Employment Laws;

 

2

 

(c)                                  provide the Leased Employees with any protective or safety equipment, as required to perform work by federal, state or local law, rule, regulation, ordinance, directive, or order;

 

(d)                                 verify and report to JAGX in an accurate and timely manner the actual monthly hours that each Leased Employee worked or was absent for any reason during the Term, for the purpose of permitting JAGX to pay each of the Leased Employees his or her earned wages, which JAGX shall use to generate payroll for each Leased Employee and make appropriate deductions and withholdings from his or her pay;

 

(e)                                  maintain adequate personnel records and related employment documentation, including but not limited to records regarding all documents relating to any accident, injury, or illness that is, is claimed to be, or may be attributable to any Leased Employee’s work, and make all such records and documentation available to JAGX upon request;

 

(f)                                   obtain and maintain in full force any insurance, other than workers’ compensation insurance or any insurance with respect to which premiums are included in the Employment Costs, that may be necessary in light of work assigned to or performed by the Leased Employees, including but not limited to any such insurance covering Leased Employees in the event of injury or illness incurred or suffered by any of them in the course of performing their duties as assigned by the Buyer and, upon request by JAGX, furnish JAGX with a certificate of insurance verifying such coverage;

 

(g)                                 execute and complete any and all documents required to perform its obligations under this Agreement within a reasonable time; and

 

(h)                                 cooperate with JAGX on employment matters related to the Leased Employees.

 

8.                                      Indemnification.

 

(a)                                 Napo agrees to indemnify and hold harmless JAGX, each of JAGX’s officers, directors, employees, and agents (collectively, the “JAGX Indemnified Parties”) from and against, and pay and reimburse the JAGX Indemnified Parties for any and all claims, demands, losses, costs, expenses, taxes and/or liabilities, including, without limitation, reasonable attorneys’ fees and expenses incident to any suit, proceeding or investigation or any claim (collectively, the “Losses”) arising out of this Agreement or relating to JAGX’s employment of the Leased Employees during the Term, other than any Losses that are due to the gross negligence or willful misconduct of any of the JAGX Indemnified Parties arising in connection with this Agreement; provided, however, that to the extent a Leased Employee renders services to both Napo and JAGX, the indemnification set forth in this paragraph with respect to Losses relating to JAGX’s employment of the Leased Employees during the Term shall only apply to Losses relating to services rendered by such Leased Employee to or for the benefit of Napo pursuant to this Agreement.

 

(b)                                 JAGX shall indemnify and hold harmless Napo and each of its officers, directors, employees, and agents (collectively, the “Napo Indemnified Parties”) from and

 

3

 

against, and pay and reimburse the Napo Indemnified Parties for, any losses that are due to the gross negligence or willful misconduct of any of the JAGX Indemnified Parties arising in connection with this Agreement.

 

9.                                      General Provisions.

 

(a)                                 Entire Agreement.  This Agreement represents the entire agreement between the parties with respect to the matters covered by this document, and supersedes all prior agreements, whether written or oral.  This Agreement may be amended only in writing, executed by all parties hereto.

 

(b)                                 No Waiver.  The failure of any party to insist upon strict adherence to any terms of this Agreement on any occasion shall not be considered a waiver or deprive that party of the right to insist later on strict adherence thereto, or thereafter to insist upon strict adherence to that term or any other term of this Agreement.  Any waiver must be in writing and signed by an authorized representative of the relevant party in order to be effective.

 

(c)                                  Notices.  All notices, requests, demands, claims and other communications hereunder (“Notices”) shall be in writing.  Any Notice hereunder shall be deemed duly given (i) upon receipt if delivered in person; (ii) on the date delivered by Federal Express, UPS, DHL or similar international courier service as established by the sender by evidence obtained from the courier; (iii) upon transmission by facsimile, provided an electronic acknowledgement of receipt is generated; or (iv) on the fifth day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid; in each case addressed to the intended recipient as set forth below (or to such other address or facsimile number as the intended recipient may request by way of an appropriate Notice given in accordance with this Section):

 

	
If   to JAGX:
    	
If   to Napo:
    
	
Karen   Wright, CFO
    	
Charles   Thompson, CFO
    
	
Jaguar   Animal Health, Inc.
    	
Napo   Pharmaceuticals, Inc.
    
	
 
    	
 
    
	
with   a copy to:
    	
with   a copy to:
    
	
 
    	
 
    
	
Donald   C. Reinke, Esq.
    	
Donald   C. Reinke, Esq.
    
	
Reed   Smith LLP
    	
Reed   Smith LLP
    

 

(d)                                 No Assignment.  Neither party shall assign this Agreement or any right, interest or benefit under this Agreement, nor delegate any of its duties or obligations hereunder, without the prior written consent of the other party.  Except as permitted by the foregoing, any attempted assignment or delegation shall be null, void, and of no effect.  Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the successors and assigns of each of the parties.

 

(e)                                  Counterparts.  This Agreement may be executed in any number of counterparts which together shall constitute one and the same instrument.  Delivery of an

 

4

 

executed counterpart of a signature page by facsimile shall be effective as delivery of a manually executed counterpart.

 

(f)                                   Governing Law.  This Agreement shall be governed by and construed under the internal laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California, without reference to principles of conflict of laws or choice of laws.

 

(g)                                 Amendments.  Neither this Agreement nor any of the terms or conditions hereof may be waived, amended or modified except by means of a written instrument duly executed by both parties.

 

(h)                                 Arbitration.  The Parties agree that any and all disputes arising out of the terms of this Agreement, their interpretation, and any of the matters herein released, shall be subject to binding arbitration in Los Angeles County before the Judicial Arbitration and Mediation Service (“JAMS”).  The Parties agree that the prevailing party in any arbitration shall be entitled to relief in any court of competent jurisdiction to enforce the arbitration award.  The Parties agree that the prevailing party in any arbitration shall be awarded its reasonable attorneys’ fees and costs.  The Parties hereby agree to waive their right to have any dispute between them resolved in a court of law by a judge or jury.

 

(i)                                    Further Assurances.  The parties, without further consideration of any kind, shall each execute and deliver, or cause to be executed and delivered, such other instruments, and take, or cause to be taken, such other action, as shall reasonably be requested by the other party hereto to more effectively carry out the terms and provisions of this Agreement.

 

(j)                                    Severability.  Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.

 

10.                               Ownership of New Technology.

 

(a)                                 New Technology.  Any and all (i) inventions (whether or not reduced to practice and whether or not patentable), (ii) works of authorship, (iii) trade secrets, know-how, confidential information (including but not limited to confidential ideas, research and development, technology, discoveries, methods, formulas, compositions, manufacturing processes, designs, specifications, clinical trial protocols, statistical analyses and other regulatory information, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals) and all other proprietary information and data (including but not limited to technical and safety, efficacy and other clinical data) conceived, developed or reduced to practice by JAGX or Napo, either jointly or individually, in whole or in part, after the date hereof and during the Term (collectively, “New Technology”) shall be owned by (i) JAGX to the extent such New Technology is within the JAGX Field of Use defined as Animal Health Care Drug Research, Development and Commercialization and (ii) Napo to the extent such New Technology is outside the JAGX Field of Use.  Each party shall disclose to the other party any New Technology promptly after it has been conceived, developed or reduced to practice.  For the

 

5

 

purposes of this Section 10, all determinations of inventorship shall be made in accordance with United States patent law.  For no additional consideration, each party (the “Assignor”) hereby assigns to the other party (the “Assignee”) all of the Assignor’s right, title and interest, worldwide, in and to any New Technology (including without limitation all intellectual property rights associated therewith and all copies and tangible embodiments thereof, in whatever form or medium) consistent with the ownership allocation described above so that sole and exclusive ownership therein resides in JAGX to the extent such New Technology is within the JAGX Field of Use and in Napo to the extent such New Technology is outside the JAGX Field of Use.  Assignor shall, at Assignee’s request and expense, execute documents and perform such acts as Assignee may deem necessary, to confirm in Assignee, all right, title and interest throughout the world, in and to any New Technology consistent with the ownership allocation set forth herein, and all patents, trademarks, copyrights and other applicable statutory protections thereon, and to enable and assist Assignee in procuring, maintaining, enforcing and defending patents, trademarks, copyrights and other statutory protections throughout the world in and to any such New Technology.  Each party shall cause each of its employees, contractors and consultants to execute and deliver an agreement assigning all of their respective right, title and interest in and to any New Technology consistent with the above ownership allocation so that sole and exclusive ownership therein resides in JAGX to the extent such New Technology is within the JAGX Field of Use and in Napo to the extent such New Technology is outside the JAGX Field of Use.

 

11.                               Confidentiality.

 

(a)                                 Use of Confidential Information.  From time to time prior to the commencement of and during the Term, each party hereto has disclosed or may disclose its confidential information (e.g., information regarding a disclosing party’s business and operations, research and development activities, pre-clinical and clinical data, regulatory strategies and submissions, products, customers, employees, financial results, contractual relationships, etc.) to the other party.  In addition, each party may, from time to time during the Term, obtain or have access to the other party’s confidential information.  As used herein, the term “confidential information” does not include information that (i) is in or comes into the public domain through no fault of the receiving party or any of its affiliates or their representatives, or (ii) is lawfully acquired without confidentiality obligations to the disclosing party from sources having the right to make such disclosure or (iii) was developed independently by the receiving party without use of any confidential information of the disclosing party.  Each party shall maintain (and cause its affiliates and subcontractors to maintain) the confidentiality of the other party’s confidential information and not to use or disclose such confidential information except as required to perform its obligations in accordance with this Agreement or as permitted hereby or by the disclosing party in writing.  If compelled to disclose any confidential information by judicial or administrative process or by requirement of law, the receiving party shall promptly notify the disclosing party in writing and, if legal protection is not obtained, may disclose only that portion of such information that is legally required to be disclosed as advised by counsel; provided that the receiving party shall exercise commercially reasonable efforts to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.  Because of the unique nature of the confidential information, the parties understand and agree that the disclosing party will suffer irreparable harm in the event that a party which receives such disclosing party’s confidential information fails to comply with any of its obligations hereunder and that monetary damages will be inadequate to compensate

 

6

 

disclosing party for such breach.  Accordingly, each party agrees that the disclosing party shall, in addition to any other remedies available to it at law or in equity, be entitled to seek injunctive relief to enforce the terms hereof.

 

(b)                                 Return of Confidential Information.                                    Upon termination of this Agreement, unless a party has a continuing right to use such confidential information pursuant to a license granted hereunder, upon request of the other party, each of the parties hereto agrees to return to the other all such confidential information of the other, or, at its option destroy such confidential information and, thereafter, certify immediately to the disclosing party that all such confidential information has been returned or destroyed.

 

7

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their authorized representatives as of the day and year first above written.

 

	
 
    	
Jaguar Animal Health, Inc.
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Karen Wright
    
	
 
    	
Its:   
    	
CFO
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Napo Pharmaceuticals, Inc.
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Charles Thompson
    
	
 
    	
Its:   
    	
CFO
    

 

8

 

EXHIBIT A

 

LEASED EMPLOYEES

 

	
Employee Name
    	
 
    	
Position
    	
 
    	
Approximate percentage of
   monthly time to be spent
   rendering services to or for
   the benefit of Napo
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Steven King
    	
 
    	
EVP Sustainable Supply, IP
    	
 
    	
TBD*
    
	
David Sesin
    	
 
    	
Chief Manufacturing Officer
    	
 
    	
TBD*
    
	
Niki Waldron
    	
 
    	
Sr. Formulation Scientist
    	
 
    	
TBD*
    
	
Bobba Venkatadri
    	
 
    	
CMC/Manufacturing
    	
 
    	
TBD*
    
	
Kevin Bohnert
    	
 
    	
Sr. Manager, Global Supply Mgmt
    	
 
    	
TBD*
    
	
Joelle Margolin
    	
 
    	
Human Resource/Legal
    	
 
    	
TBD*
    
	
Rocky Ordonez
    	
 
    	
Analyst/Exec Admin
    	
 
    	
TBD*
    
	
Roger Waltzman
    	
 
    	
Chief Scientific Officer
    	
 
    	
TBD*
    
	
Rustom Masalawa
    	
 
    	
SVP, Intl Markets
    	
 
    	
TBD*
    
	
Guy Mazula
    	
 
    	
Controller
    	
 
    	
TBD*
    
	
David Upchurch
    	
 
    	
VP Global Supply Chain
    	
 
    	
TBD*
    
	
Nancy McCabe
    	
 
    	
Head of Quality
    	
 
    	
TBD*
    

 

*To be calculated and submitted monthly by all JAGX leased employees to JAGX’s Payroll Department who will invoice NAPO for the monthly JAGX Leased Employees

 

9Exhibit 10.2

 

AMENDMENT NO. 1 TO EMPLOYEE LEASING AND OVERHEAD ALLOCATION
 AGREEMENT

 

THIS AMENDMENT NO. 1 TO EMPLOYEE LEASING AND OVERHEAD ALLOCATION AGREEMENT (this “Amendment”), dated as of March 2, 2017 (the “Amendment Effective Date”) is entered into by and between Jaguar Animal Health, Inc., (“JAGX”), and Napo Pharma (“Napo”).  Vendor and Distributor are sometimes referred to herein individual as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, the Parties have previously entered into an Employee Leasing and Overhead Allocation Agreement (the “Agreement”) dated as of July 1, 2016; and

 

WHEREAS, the Parties desire to amend and modify the Agreement.

 

NOW, THEREFORE, for and in consideration of the foregoing and the mutual covenants and agreements contained in this Amendment, the Agreement is hereby amended as follows:

 

1.                                      Definitions.  All capitalized terms used but not otherwise defined herein shall have the meaning set forth in the Agreement.

 

2.                                      Amendments to the Agreement.

 

a.                                      Section 1 TERM is hereby deleted in its entirety and replaced with the following:

 

“The assistance period (“Assistance Period”) shall commence on the date hereof and shall terminate once the Parties have completed a successful merger OR terminated pursuant to Paragraph 5 hereof.”

 

3.                                      Effect of this Amendment.  This Amendment shall become effective as of the Amendment Effective Date.  There are no further changes to the terms of the Agreement.  Except as would be inconsistent with the terms of this Amendment, all other terms and conditions of the Agreement shall remain in full force and effect and be unaffected by this Amendment.

 

4.                                      Facsimile and Counterparts.  This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and all of which, taken together, shall constitute one and the same instrument.  Delivery of an executed counterpart of a signature page of this Amendment (and each amendment, modification and waiver in respect of it) by facsimile or other electronic transmission, if identified, legible and complete, will be regarded as an original signature and shall be as effective as delivery of a manually executed original counterpart of each such instrument.

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered as of the Amendment Effective Date.

 

	
 
    	
Jaguar   Animal Health, Inc.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Karen Wright
    
	
 
    	
 
    	
Name:   Karen Wright
    
	
 
    	
 
    	
Title:   CFO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Napo   Pharma
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Charles Thompson
    
	
 
    	
 
    	
Name:   Charles Thompson
    
	
 
    	
 
    	
Title:   CFO
    

 

[Signature Page to Amendment No. 1 to Amended and Restated License Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]